- Home
- SNTI vs VYNE Comparison
SNTI vs VYNE Comparison
Compare SNTI & VYNE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SNTI | VYNE |
|---|---|---|
| Founded | 2016 | 2003 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 22.8M | 20.0M |
| IPO Year | 2021 | 2017 |
Fundamental Metrics
Financial Performance| Metric | SNTI | VYNE |
|---|---|---|
| Price | $1.00 | $0.59 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 4 | 1 |
| Target Price | ★ $9.00 | N/A |
| AVG Volume (30 Days) | 109.5K | ★ 299.0K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 33.33 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $150.00 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.80 | $0.29 |
| 52 Week High | $5.10 | $1.98 |
Technical Indicators
Market Signals| Indicator | SNTI | VYNE |
|---|---|---|
| Relative Strength Index (RSI) | 54.59 | 56.75 |
| Support Level | $0.80 | $0.55 |
| Resistance Level | $1.02 | $0.60 |
| Average True Range (ATR) | 0.05 | 0.02 |
| MACD | 0.02 | -0.00 |
| Stochastic Oscillator | 90.34 | 71.74 |
Price Performance
Historical ComparisonAbout SNTI Senti Biosciences Inc.
Senti Biosciences Inc is a clinical-stage biotechnology company developing next-generation cell and gene therapies engineered with its gene circuit platform technologies for patients living with incurable diseases. The product candidates utilize allogeneic chimeric antigen receptor natural killer (CAR-NK) cells outfitted with its gene circuit technologies in various oncology indications. The company product candidates include SENTI-202, a Logic Gated off-the-shelf CAR-NK cell therapy designed to target and eliminate cancer cells while sparing the healthy bone marrow; and SENTI-301A for the treatment of hepatocellular carcinoma.
About VYNE VYNE Therapeutics Inc.
VYNE Therapeutics Inc is a biopharmaceutical company focused on developing proprietary, innovative and differentiated therapies for the treatment of immuno-inflammatory conditions. Its advanced product candidate is FMX114, which is being evaluated for the potential treatment of mild-to-moderate AD (atopic dermatitis). The company is also in the pre-clinical stages of developing products containing BET (Bromodomain and Extra-Terminal Domain) inhibitor compounds. Its products include AMZEEQ, ZILXI, and FCD105.